DEVELOPMENT BY DESIGN
LIVE

Serial Number

86873967

Owner

Hovione Scientia Limited

Attorney

Mainak H. Mehta

Filing Date

Jan 13, 2016

Add to watchlist:

No watchlists yet
View on USPTO

DEVELOPMENT BY DESIGN Trademark

Serial Number: 86873967 • Registration: 5220043

DEVELOPMENT BY DESIGN is a trademark filed by Hovione Scientia Limited on January 13, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). The application is currently registered and active.

Owner Contact Info

Hovione Scientia Limited (16 trademarks)

Loughbeg

Entity Type: 99

Trademark Details

Filing Date

January 13, 2016

Registration Date

June 6, 2017

Goods & Services

[ Compositions for medical and veterinarian use, namely, chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals; diagnostic preparations for medical purposes; chemical products for pharmaceutical use, namely, chemical preparations for the prevention, diagnosis, treatment or improvement of conditions and disorders, namely, inflammatory, allergical, oncological, degenerative, genetic, traumatic, tumoural, pressure, poisoning, mutation, sepsis, psychiatric, obese, eating, addictive, sexual, sleep, and infectious conditions and disorders, namely, bacterial, viral, fungal or parasitic conditions and disorders, all of the above related to skin, musculo-skeletal, cardiac, neurological, cellular, vascular, hematological, respiratory, digestive, genital, urinary, reproductive, sensorial, metabolic, endocrine, lymphatic, immune or nervous systems, as well as pain management, for use by humans or animals ]

[ Active chemical ingredients for use in the manufacture of pharmaceuticals ]

research and development of manufacturing processes for the pharmaceutical industry; research in the field of optimizing manufacturing processes for the pharmaceutical industry

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Jun 6, 2026 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Jun 7, 2024 NAS8
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Jun 7, 2024 8.PR
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
May 21, 2024 EROP
POST REGISTRATION ACTION MAILED - SEC. 8
Nov 21, 2023 PRA8
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 21, 2023 APRE
TEAS SECTION 8 RECEIVED
Aug 8, 2023 ES8R
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 6, 2022 REM1
REGISTERED-SUPPLEMENTAL REGISTER
Jun 6, 2017 R.SR
LAW OFFICE PUBLICATION REVIEW COMPLETED
May 4, 2017 PREV
ASSIGNED TO LIE
Apr 25, 2017 ALIE
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Mar 27, 2017 CNTA
EXAMINER'S AMENDMENT ENTERED
Mar 27, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 27, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 27, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 27, 2017 CNEA
AMENDMENT FROM APPLICANT ENTERED
Mar 27, 2017 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 27, 2017 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Mar 23, 2017 ERFR
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Sep 26, 2016 GNS1
SUBSEQUENT FINAL EMAILED
Sep 26, 2016 GNSF
SUBSEQUENT FINAL REFUSAL WRITTEN
Sep 26, 2016 CFRC
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 25, 2016 GNFN
FINAL REFUSAL E-MAILED
Sep 25, 2016 GNFR
FINAL REFUSAL WRITTEN
Sep 25, 2016 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 26, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 25, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 25, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 25, 2016 GNRN
NON-FINAL ACTION E-MAILED
Feb 25, 2016 GNRT
NON-FINAL ACTION WRITTEN
Feb 25, 2016 CNRT
ASSIGNED TO EXAMINER
Feb 18, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 19, 2016 NWOS
NEW APPLICATION ENTERED
Jan 16, 2016 NWAP